ArticleHormones (Athens, Greece)2026
Immune checkpoint inhibitors and metabolic events: results from a European safety analysis.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) include programmed death-1 receptor (PD1) inhibitors, programmed death-ligand 1 (PDL1) inhibitors, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors. The use of ICIs has been associated with multiple endocrine immune-related adverse events. This study aims to describe Individual Case Safety Reports (ICSRs) of metabolic events reported in the European database (Eudravigilance, EV) and to compare the reporting frequency of metabolic effects between ICIs.
methodsA retrospective, European, pharmacovigilance study was conducted to evaluate ICSRs reporting metabolic events with ICIs between 2018 and 2022.
findingsA total of 6,220 ICSRs reporting an ICI as a suspected drug and at least one metabolic event were identified. The most reported ICI was pembrolizumab (N = 2,466; 39.6%), followed by nivolumab (N = 1,823; 29·3%). The most reported glycemic alteration was type 1 diabetes mellitus (N = 1,001; 13·2%), followed by diabetic ketoacidosis (N = 563, 7·4%). The use of anti-PD1 was associated with a higher reporting of type 1 diabetes mellitus than anti-CTLA4 (ROR, 4·85; 95%CI, 1·56 - 15·09) and anti-PDL1 (ROR, 1·74; 95%CI, 1·41 - 2·13), while no difference was found between anti-PDL1 and anti-CTLA4 (Fig. 4A). Moreover, anti-PD1 was associated with a higher reporting of type 2 diabetes than anti-PDL1 (ROR, 2·06; 95%CI, 1·03-4·10). In addition, the reporting probability of type 1 diabetes mellitus was higher with age ≥ 65 years than < 65 years (ROR, 15·74; 95%CI, 10·44 - 23·73), while no significant difference was found for type 2 diabetes mellitus.
interpretationIn conclusion, the use of anti-PD1 has been associated with higher reporting of both type 1 and type 2 diabetes. Larger longitudinal studies are needed to interpret these reports and to advance hypotheses of pathogenetic mechanisms of this association.
Indexed as
Identifiers
41094346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.